FDA Issues Warning to Six Companies Selling Over-the-Counter Topical Pain Relief Products with Excessive Lidocaine Concentration

FDA cautions that widely used pain-relief creams could present serious health hazards

The U.S. Food and Drug Administration (FDA) has issued a warning to six companies selling over-the-counter topical pain-relief products with higher-than-allowed concentrations of lidocaine, a local anesthetic. The FDA’s Office of Compliance in the Center for Drug Evaluation and Research emphasized the risks associated with these products, stating that they should not be on the market due to their potential harm to consumers.

Jill Furman, director of the Office of Compliance in the FDA’s Center for Drug Evaluation and Research, emphasized the risks associated with these products. The problem with these products lies in their excessive lidocaine content, which can lead to serious side effects such as irregular heartbeat, seizures, and breathing difficulties when used on a large area of skin or irritated skin.

To prevent adverse effects, the FDA recommends avoiding products containing more than 4% lidocaine, refraining from usage on large areas of skin, and avoiding wrapping the product with dressings or plastic wraps. Some of the products cited by the FDA in their warning include TKTX Numb Maximum Strength Pain Reliever, NumbSkin Lidocaine Numbing Creams, and Signature Tattoo Numbing Cream.

It is essential to heed these warnings to protect your health and well-being while undergoing cosmetic procedures. Interested individuals can refer to the FDA’s official press release for more detailed information on the specific products mentioned in their warning.

Leave a Reply